P53 downregulates the gene expression of mitochondrial aconitase in human prostate carcinoma cells

Prostate

Volumn 71, Issue 1, 2011, Pages 62-70

  Tsui, Ke Hung ^a   Feng, Tsui Hsia ^b   Lin, Yu Fen ^b   Chang, Phei Lang ^a   Juang, Horng Heng ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

camptothecin; LNCaP; mACON; p53; PC 3; pifithrin ; promoter; prostate

Indexed keywords

ACONITATE HYDRATASE; CAMPTOTHECIN; PIFITHRIN ALPHA; PROTEIN P53;

ARTICLE; CARCINOMA CELL; CELL STRAIN LNCAP; CONSENSUS SEQUENCE; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DOWN REGULATION; ENZYME ACTIVITY; EXPRESSION VECTOR; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CARCINOMA; REGULATORY MECHANISM; TRANSIENT EXPRESSION; TRANSIENT TRANSFECTION; WILD TYPE;

ACONITATE HYDRATASE; CAMPTOTHECIN; CARCINOMA; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; MALE; MITOCHONDRIA; MUTATION; PROSTATIC NEOPLASMS; RESPONSE ELEMENTS; THIAZOLES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78649626185     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21222     Document Type: Article

References (39)

1. Emptage MH, Kent TA, Kennedy MC, Beinert H, Munck E,. Mossbauer and EPR studies of activated aconitases: Development of a localized valence state at a subsite of the [4Fe-4S] cluster on binding of citrate. Proc Natl Acad Sci USA 1983; 80: 4674-4678.
2. Cooper JE, Farid I,. The role of citric acid in the physiology of the prostate. Lactic/citrate ratio in benign and malignant prostatic homogenates as an index of prostatic malignancy. J Urol 1964; 92: 533-536.
3. Costello LC, Franklin RB,. The bioenergetic theory of prostate malignancy. Prostate 1994; 25: 162-166.
4. Singh KK, Desouki MM, Franklin RB, Costello LC,. Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues. Mol Cancer 2006; 5: 14.
5. Juang HH,. Modulation of mitochondrial aconitase on the bioenergy of human prostate carcinoma cells. Mol Genet Metab 2004; 81: 244-252.
6. Franklin RB, Costello LC,. Zinc as an anti-tumor agent in prostate cancer and in other cancers. Arch Biochem Biophys 2007; 463: 211-217.
7. Juang HH,. Modulation of iron on mitochondrial aconitase expression in human prostatic carcinoma cells. Mol Cell Biochem 2004; 265: 185-194.
8. Juang HH, Hsieh M-L, Tsui KH,. Testosterone modulates mitochondrial aconitase in the full-length human androgen receptor-transfected PC-3 prostatic carcinoma cells. J Mol Endocrinol 2004; 33: 121-132.
9. Juang HH,. Cyclic Adenosine 3′,5′- Monosphosphate mediate prolactin regulation of mitochondrial aconitase in human prostate carcinoma cells. Mol Cell Endocrinol 2004; 219: 141-149.
10. Juang HH,. Nitroprusside stimulates mitochondrial aconitase gene expression through the cyclic adenosine 3′,5′-monosphosphate signal transduction pathway in human prostate carcinoma cells. Prostate 2004; 61: 92-102.
11. Feng T-H, Tsui KH, Juang HH,. Cholesterol modulation of the expression of mitochondrial aconitase in human prostatic carcinoma cells. Chin J Physiol 2005; 48: 93-100.
12. Tsui KH, Chang P-L, Juang HH,. Zinc blocks gene expression of mitochondrial aconitase in human prostatic carcinoma cells. Int J Cancer 2006; 118: 609-615.
13. Tsui KH, Chang P-L, Juang HH,. Maganese antagonizes iron blocking the mitochondrial aconitase expression in human prostate carcinoma cells. Asian J Androl 2006; 8: 307-315.
14. Tsui KH, Feng T-H, Chang P-L, Juang HH,. Callium deregulate mitochondrial aconitase gene in the human prostate carcinoma cells. Androl Update 2007; 1: 304-312.
15. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, van Tuinen P, Ledbetter DH, Barker DF, Nakamura Y, White R, Vogelstein B,. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989; 224: 217-221.
16. Osman I, Drobnjak M, Fazzari M, Scher HI, Cordon-Cardo C,. Inactivation of the p53 pathway in prostate cancer: Impact on tumor progression. Clin Cancer Res 1999; 5: 2082-2088.
17. Kruse J-P, Cu W,. Modes of p53 regulation. Cell 2009; 137: 609-622.
18. Bensaad K, Tsuruta A, Selak MA, Vidal MNC, Nakano K, Bartrons R, Gottlieb E, Vousden KH,. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126: 107-120.
19. Bensaad K, Vousden KH,. p53: New roles in metabolism. Trends Cell Biol 2007; 17: 286-291.
20. Smith TA, Sharma RI, Thompson AM, Paulin FE,. Tumor 18F-FGD incorporation is enhanced by attenuation of p53 function in breast cancer cells in vitro. J Nucl Med 2006; 47: 1525-1530.
21. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, Martinez D, Carnero A, Beach D,. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005; 65: 177-185.
22. Pizzolato JF, Saltz LB,. The camptothecins. Lancet 2003; 361: 2235-2242.
23. Bhattacharya S, Ray RM, Johnson LR,. Role of polyamines in p53-dependent apoptosis of intestinal epithelial cells. Cell Signal 2009; 21: 509-522.
24. Mizutani K, Matsumoto K, Hasegawa N, Deguchi T, Nozawa Y,. Expression of culsterin, XIAP and surviving, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and CPT-sensitive LNCaP cells. Exp Oncol 2006; 28: 209-215.
25. Tsui KH, Chang P-L, Lin H-T, Juang HH,. Down-regulation of the prostate specific antigen promoter by p53 in human prostate cancer cells. J Urol 2004; 172: 2035-2039.
26. Tsui KH, Hsieh WC, Lin MH, Chang P-L, Juang HH,. Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2. Prostate 2008; 68: 610-619.
27. Boostein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC,. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993; 53: 3369-3373.
28. Cowen D, Salem N, Ashoori F, Meyn R, Meistrich ML, Roth JA, Pollack A,. Prostate cancer radiosenitization in vivo with adenovirus-mediated p53 gene therapy. Clin Cancer Res 2000; 6: 4402-4408.
29. Girinsky T, Koumenis C, Graeber TG, Peehl DM, Giaccia AJ,. Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents. Cancer Res 1995; 55: 3726-3731.
30. Olovnikov IA, Kravchenko JE, Chumakov PM,. Homeostatic functions of the p53 tumor suppressor: Regulation of energy metabolism and antioxidant defense. Semin Cancer Biol 2009; 19: 32-41.
31. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, Hwang PM,. p53 regulates mitochondrial respiration. Science 2006; 312: 1650-1653.
32. Costello LC, Franklin RB,. The intermediary metabolism of the prostate: A key to understanding the pathogenesis and progression of prostate malignancy. Oncology 2000; 59: 269-282.
33. Hochachka PW, Rupert JL, Goldenberg L, Gleave M, Kozlowski P,. Going malignant: The hypoxia-cancer connection in the prostate. BioEssays 2002; 24: 749-757.
34. Roepke M, Diestel A, Bajbouj K, Walluscheck D, Schonfeld P, Roessner A, Schneider-Stock R, Gali-Muhtasib H,. Lack of p53 augments thymoquinone-induced apoptosis and caspase activation in human osteosarcoma cells. Cancer Biol Ther 2007; 6: 160-169.
35. Rocha S, Campbell KJ, Roche KX, Perkins ND,. The p53-inhibitor pifithrin-α inhibits firefly luciferase activity in vivo and in vitro. BMC Mol Biol 2003; 4: 9.
36. El-Deiry WS,. Regulation of p53 downstream genes. Semin Cancer Biol 1998; 8: 345-357.
37. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, Liu J, Zhao XD, Chew JL, Lee YL, Kuznetsov VA, Sung WK, Miller LD, Lim B, Liu ET, Yu Q, Ng HH, Ruan Y,. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006; 124: 207-219. (Pubitemid 43069320)
38. Liu Y, Lagowski JP, Vanderbeek GE, Kulesz-Martin MF,. Facilitated search for specific genomic targets by p53 C-terminal basic DNA binding domain. Cancer Biol Ther 2004; 3: 1102-1108.
39. Cawley S, Bekiranov S, Ng HH, Kapranov P, Sekinger EA, Kampa D, Piccolboni A, Sementchenko V, Cheng J, Williams AJ, Wheeler R, Wong B, Drenkow J, Yamanaka M, Patel S, Brubaker S, Tammana H, Helt G, Struhl K, Gingeras TR,. Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell 2004; 116: 499-509.